Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07040774 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Study acronym: EU-IFNp
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Site details revised at 3 of 32 sitesv6
  2. Minor Site details revised at 6 of 32 sitesv5
  3. Notable Start date: Jul 1, 2025 to Oct 1, 2025
    • Primary and study completion dates: May 2045 to Oct 2045
    • Site contacts updated at 1 of 32 sites
    v4
  4. Minor Study sites: 16 to 32v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 16 of 16 sites
    v2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies. The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies. The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Trial Details
NCT Number NCT07040774
Lead Sponsor Imagine Institute
Conditions
(from sponsor)
Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases
Related terms Autoimmune Diseases, Genetic Diseases, Inborn, Immune System Diseases, Nervous System Diseases
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov